RxDoctor Payments Data

Kian Kaz, MD

Ophthalmology · Newport News, VANPI 1588657837

Payments from drug & device makers

$2,830in general payments, 2019–2025

Across 127 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$656
  • Mallinckrodt Hospital Products Inc.$337
  • Bausch & Lomb Americas Inc.$255
  • Sun Pharmaceutical Industries Inc.$250
  • Tarsus Pharmaceuticals, Inc.$205
  • Oyster Point Pharma, Inc.$161
  • plus $965 from 17 others

What the payments were for

  • Food & beverage$2,71296%
  • Education$1184%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,830 in reported general payments places this provider in the 70th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$846,361
Medicare patients
1,718
Services billed
11,187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine60$68,781
VyzultaLatanoprostene Bunod142$61,051
CombiganBrimonidine Tartrate/Timolol85$42,266
XiidraLifitegrast35$41,496
RhopressaNetarsudil Mesylate55$28,704
SimbrinzaBrinzolamide/Brimonidine Tart88$27,654
LumiganBimatoprost50$25,475
Cyclosporine24$19,525
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol102$16,278
Loteprednol Etabonate44$12,391
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat469$10,990
RocklatanNetarsudil Mesylat/Latanoprost20$9,993
Latanoprost829$8,152
Brimonidine Tartrate305$7,474
Prednisolone Acetate101$5,983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$656$136,522195 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$255$102,547177 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$116$38,69775 claims
AlconSimbrinza$54$27,65488 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$69$12,39144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →